Giuseppe Gargiulo1, MD, PhD; Alessandra Marenna1, PhD; Luca Sperandeo1, MD; Lina Manzi1, MD; Marisa Avvedimento1, MD; Fiorenzo Simonetti1, MD; Mario Enrico Canonico1, MD; Roberta Paolillo1, PhD; Alessandra Spinelli1, BSc; Francesco Borgia1, MD, PhD; Luigi Diserafino1, MD, PhD; Anna Franzone1, MD, PhD; Eugenio Stabile2, MD, PhD; Raffaele Piccolo1, MD, PhD; Plinio Cirillo1, MD, PhD; Marco Valgimigli3, MD, PhD; Giovanni Esposito1, MD, PhD
1. Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy; 2. Cardiovascular Department, Azienda Ospedaliera Regionale "San Carlo," Potenza, Italy; 3. Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), Lugano, Switzerland
Complex percutaneous coronary intervention (PCI) patients have a greater risk of periprocedural complications, which could possibly be associated with poor short- and long-term prognoses.
Cangrelor, an intravenous P2Y12 receptor inhibitor with rapid onset and offset of platelet inhibition, reduces the risk of thrombotic complications compared with clopidogrel in patients undergoing elective or emergent PCI. Pharmacodynamic (PD) investigations have been conducted in various clinical settings, with various assays of platelet reactivity assessment and with some contrasting data regarding the degree of platelet inhibition and rates of high residual platelet reactivity (HRPR), particularly in patients with ST-segment elevation ...